。ACB announced that it has commenced sales of cannabis oils to German pharmacies following receipt of all necessary approvals from the Canadian and German regulatory authorities. Pedanios 5/1 drops have become the first extract derived oil product compliant with the German monograph for in-pharmacy preparation.
。Aurora Cannabis now has a presence in 24 countries. No other competitor even comes close to that number.
。Jefferies analyst Owen Bennett rates ACB stock a Buy with C$12.00 price target. The analyst views Germany as a “key” market to making cannabis an international growth industry, citing both “strong patient growth” and high margins on marijuana sales into the Teutonic state as making Germany an attractive market.
。Cowen analyst Vivien Azer likes Aurora Cannabis (ACB) and thinks the stock could jump more than 30% above its current level. Azer's top reason for liking Aurora Cannabis so much is its production capacity. She wrote to clients that Aurora's capacity provides the company "with the necessary infrastructure to weather early storms in adult use while continuing to grow higher-value revenues in the medical market."
。Technically, ACB is forming a bullish Cup and Handle pattern and looks ready to breakout. On breaking out, 10 to 10.5 looks like a reasonable target.
。Aurora Cannabis now has a presence in 24 countries. No other competitor even comes close to that number.
。Jefferies analyst Owen Bennett rates ACB stock a Buy with C$12.00 price target. The analyst views Germany as a “key” market to making cannabis an international growth industry, citing both “strong patient growth” and high margins on marijuana sales into the Teutonic state as making Germany an attractive market.
。Cowen analyst Vivien Azer likes Aurora Cannabis (ACB) and thinks the stock could jump more than 30% above its current level. Azer's top reason for liking Aurora Cannabis so much is its production capacity. She wrote to clients that Aurora's capacity provides the company "with the necessary infrastructure to weather early storms in adult use while continuing to grow higher-value revenues in the medical market."
。Technically, ACB is forming a bullish Cup and Handle pattern and looks ready to breakout. On breaking out, 10 to 10.5 looks like a reasonable target.
Aurora Cannabis Inc.（ACB 8.15）生产和销售医用大麻产品。 它在大麻价值链的各个部分垂直整合和横向多样化，从设施工程和设计到大麻育种，遗传研究，生产，衍生物，高附加值产品开发，家庭种植，批发和零售分销。
。ACB宣布，在收到加拿大和德国监管机构的所有必要批准后，已开始向德国药房销售大麻油。 Pedanios 5/1滴剂已成为第一种符合德国药房制剂专论的提取物衍生油品。
。ACB现在在24个国家开展业务。没有其他竞争者甚至接近这个数字。
。杰富瑞分析师欧文贝内特（Owen Bennett）将ACB股票评级为买入，目标价为12.00加元。该分析师将德国视为使大麻成为国际增长型行业的“关键”市场，理由是“强劲的患者增长”以及大豆销售到条顿州的高利润率使得德国成为一个具有吸引力的市场。
。Cowen分析师Vivien Azer喜欢Aurora Cannabis（ACB）并认为该股票的价格可能会升至比当前水平高出30％以上。 Azer喜欢Aurora Cannabis的首要原因是它的生产能力。她写信给客户称ACB提供了客户“有必要的基础设施以抵御成人使用的风暴，同时继续在医疗市场增加更高的营业额。”
。从技术上讲，ACB正在形成一个看涨的杯状图形，并准备突破。 突破后，10到10.5看起来像是一个合理的目标价。
No comments:
Post a Comment